Literature DB >> 1316609

Natural human antibodies to gamma interferon interfere with the immunomodulating activity of the lymphokine.

A Turano1, A Balsari, E Viani, S Landolfo, L Zanoni, F Gargiulo, A Caruso.   

Abstract

Natural antibodies to gamma interferon (IFN-gamma) were found in patients suffering from different viral diseases and, at a lower titer, in healthy individuals. Such antibodies were affinity-purified and studied for their capability to interfere in vitro with the antiviral and immunomodulating activity of IFN-gamma. Data obtained show that these human anti-IFN-gamma antibodies have no inhibitory effect on the antiviral activity of IFN-gamma. On the contrary, they are able to inhibit the expression of Fc receptor sites and HLA-DR antigens induced by IFN-gamma on the U-937 cells, a human monocytoid/macrophage-derived cell line. These antibodies can also interfere in a mixed lymphocyte culture (MLC) with the proliferation of lymphocytes and the generation of cytotoxic lymphocytes. However, they showed only a moderate inhibitory effect on the cytotoxicity generated in MLC to K-562 cells. Human antibodies capable of interfering with the immunomodulating activities of IFN-gamma might open up a new field in clinical therapy for those diseases that carry evidence of activated cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316609      PMCID: PMC49099          DOI: 10.1073/pnas.89.10.4447

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Interferons and their actions.

Authors:  S Pestka; J A Langer; K C Zoon; C E Samuel
Journal:  Annu Rev Biochem       Date:  1987       Impact factor: 23.643

2.  Auto-antibodies to tumour necrosis factor alpha in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections.

Authors:  A Fomsgaard; M Svenson; K Bendtzen
Journal:  Scand J Immunol       Date:  1989-08       Impact factor: 3.487

3.  Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 in human B cell proliferation. Evidence that they act at different times after B cell activation.

Authors:  S Romagnani; G M Giudizi; F Almerigogna; R Biagiotti; A Alessi; C Mingari; C M Liang; L Moretta; M Ricci
Journal:  Eur J Immunol       Date:  1986-06       Impact factor: 5.532

4.  Gamma-interferon: the match that lights the fire?

Authors:  A Billiau
Journal:  Immunol Today       Date:  1988-02

5.  Clinical significance of anti-IFN-alpha antibody titres during interferon therapy.

Authors:  P von Wussow; M Freund; B Block; H Diedrich; H Poliwoda; H Deicher
Journal:  Lancet       Date:  1987-09-12       Impact factor: 79.321

6.  Differential antiviral effects of interferon in three murine cell lines.

Authors:  G C Sen; R E Herz
Journal:  J Virol       Date:  1983-03       Impact factor: 5.103

7.  Establishment and characterization of a human histiocytic lymphoma cell line (U-937).

Authors:  C Sundström; K Nilsson
Journal:  Int J Cancer       Date:  1976-05-15       Impact factor: 7.396

8.  Anti-interferon-gamma antibodies in sera from HIV infected patients.

Authors:  A Caruso; I Foresti; G Gribaudo; C Bonfanti; P Pollara; A Dolei; S Landolfo; A Turano
Journal:  J Biol Regul Homeost Agents       Date:  1989 Jan-Mar       Impact factor: 1.711

9.  Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.

Authors:  P M Peters; J R Ortaldo; M R Shalaby; L P Svedersky; G E Nedwin; T S Bringman; P E Hass; B B Aggarwal; R B Herberman; D V Goeddel
Journal:  J Immunol       Date:  1986-10-15       Impact factor: 5.422

10.  In vivo treatment of (NZB X NZW)F1 lupus-like nephritis with monoclonal antibody to gamma interferon.

Authors:  C O Jacob; P H van der Meide; H O McDevitt
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

View more
  7 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic, and inflammatory diseases.

Authors:  D R Lucey; M Clerici; G M Shearer
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

3.  Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.

Authors:  Li Xue; Adrienne Clements-Egan; Lakshmi Amaravadi; Mary Birchler; Boris Gorovits; Meina Liang; Heather Myler; Shobha Purushothama; Marta Starcevic Manning; Crystal Sung
Journal:  AAPS J       Date:  2017-11-06       Impact factor: 4.009

4.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

5.  Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma.

Authors:  Beate Kampmann; Cheryl Hemingway; Alick Stephens; Robert Davidson; Anna Goodsall; Suzanne Anderson; Mark Nicol; Elisabeth Schölvinck; David Relman; Simon Waddell; Paul Langford; Brian Sheehan; Lynn Semple; Katalin A Wilkinson; Robert J Wilkinson; Stanley Ress; Martin Hibberd; Michael Levin
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

6.  Autoantibodies induced by chimeric cytokine-HIV envelope glycoprotein immunogens.

Authors:  Gözde Isik; Thijs van Montfort; Nancy P Y Chung; John P Moore; Rogier W Sanders
Journal:  J Immunol       Date:  2014-04-11       Impact factor: 5.422

7.  Enhanced immunogenicity of HIV-1 envelope gp140 proteins fused to APRIL.

Authors:  Gözde Isik; Kwinten Sliepen; Thijs van Montfort; Rogier W Sanders
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.